Log in

NASDAQ:AMRNAmarin Stock Price, Forecast & News

$6.86
+0.10 (+1.48 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.76
Now: $6.86
$6.89
50-Day Range
$6.42
MA: $6.74
$7.05
52-Week Range
$3.95
Now: $6.86
$26.12
Volume2.65 million shs
Average Volume10.24 million shs
Market Capitalization$2.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.62
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More
Amarin logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$429.76 million
Book Value$1.54 per share

Profitability

Net Income$-22,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.64 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$6.86
+0.10 (+1.48 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amarin (NASDAQ:AMRN) Frequently Asked Questions

How has Amarin's stock price been impacted by COVID-19?

Amarin's stock was trading at $12.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRN stock has decreased by 45.4% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amarin?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amarin
.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. The biopharmaceutical company earned $133.72 million during the quarter, compared to analysts' expectations of $149.48 million. Amarin had a negative return on equity of 2.16% and a negative net margin of 2.30%. Amarin's quarterly revenue was up 33.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 EPS.
View Amarin's earnings history
.

What price target have analysts set for AMRN?

13 brokerages have issued 1 year price targets for Amarin's stock. Their forecasts range from $4.00 to $51.00. On average, they anticipate Amarin's stock price to reach $17.23 in the next twelve months. This suggests a possible upside of 151.2% from the stock's current price.
View analysts' price targets for Amarin
.

Has Amarin been receiving favorable news coverage?

Press coverage about AMRN stock has been trending neutral this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Amarin
.

Are investors shorting Amarin?

Amarin saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 44,040,000 shares, an increase of 15.3% from the February 13th total of 38,180,000 shares. Based on an average daily trading volume, of 8,400,000 shares, the days-to-cover ratio is currently 5.2 days.
View Amarin's Short Interest
.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), Alibaba Group (BABA), Gilead Sciences (GILD), Netflix (NFLX), Novavax (NVAX) and Tesla (TSLA).

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (1.37%), Oracle Investment Management Inc. (0.56%), Fairmount Funds Management LLC (0.36%), Point72 Asset Management L.P. (0.29%), First Light Asset Management LLC (0.28%) and C WorldWide Group Holding A S (0.24%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin
.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Cormorant Asset Management LP, Trexquant Investment LP, Hudson Bay Capital Management LP, Healthcare Value Capital LLC, AE Wealth Management LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Amarin company stock in the last year include John F Thero, and Lars Ekman.
View insider buying and selling activity for Amarin
.

Which major investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Fairmount Funds Management LLC, Cubist Systematic Strategies LLC, Frontier Capital Management Co. LLC, First Light Asset Management LLC, Tekla Capital Management LLC, Spring Creek Investment Management LLC, and C WorldWide Group Holding A S.
View insider buying and selling activity for Amarin
.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $6.86.

How big of a company is Amarin?

Amarin has a market capitalization of $2.64 billion and generates $429.76 million in revenue each year. The biopharmaceutical company earns $-22,650,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.